<DOC>
	<DOCNO>NCT02555111</DOCNO>
	<brief_summary>Open randomize therapeutic study ass efficacy Xarelto 15mg/day recurrence thromboembolic event compare untreated group patient chronic portal vein thrombosis without high risk thrombophilia .</brief_summary>
	<brief_title>Xarelto Versus Treatment Prevention Recurrent Thrombosis Patients With Chronic Portal Vein Thrombosis .</brief_title>
	<detailed_description>Chronic portal vein thrombosis ( PVT ) rare disease , affect young patient , characterize permanent obstruction portal vein trunk cause portal hypertension . In 60-70 % case related high risk , moderate mild prothrombotic risk factor . Accordingly , 2 type complication PVT : ( ) gastrointestinal haemorrhage relate portal hypertension ; ( ii ) recurrent thrombosis . Recurrent thrombosis dread complication may lead intestinal infarction relate mortality 20-60 % high risk intestinal insufficiency . Gastrointestinal haemorrhage relate portal hypertension occur 20 % patients/year . It less frequent patient treat medical endoscopic prophylaxis variceal bleeding . Retrospective data show anticoagulation worsen prognosis , may conversely improve . Thus , patient risk gastrointestinal bleeding due portal hypertension mild moderate risk recurrent thrombosis , benefit-risk ratio anticoagulation therapy unclear . The aim open randomise trial ass efficacy Xarelto 15mg/day , new oral factor Xa inhibitor , recurrence thromboembolic event risk major bleeding compare untreated group patient chronic portal vein thrombosis without high risk thrombophilia . This national , multicentric , interventional study . 15 french center already agree participate . 296 patient include 2 year period 2 4 year treatment period . All data collect informed consent obtain .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>80 year old &gt; Adults &gt; 18 year old Patients Either affect cavernous portal , constitute diagnostic radiological criterion , treat anticoagulant Or acute portal thrombosis history date back 6 month , document angiography angioMRI ; follow repermeabilize . Patient use prophylaxis gastrointestinal bleeding portal hypertension , accord current consensus recommendation patient cirrhosis Barrier contraception intrauterine device ( without progestin ) , woman childbearing age , progestin alone . Do use combine hormonal contraception . Presence high risk factor recurrence thrombosis veinous review medical file validation committee compose hepatologist hematologist physician hemostasis specialist . Disease relevant coagulopathy bleed risk clinically relevant ( platelet &lt; 50 000 , TP &lt; 30 % without AVK Factor V &lt; 30 % ou fibrinogen &lt; 0.8 ) Cirrhosis clinically relevant histological test Budd Chiari syndrome . Personnel first degree familial past history spontaneous ( unprovoked ) deep vein thrombosis require anticoagulant treatment Pregnancy breast feed woman Past history mesenteric infarction Absolute necessity anticoagulation whatever cause Galactose intolerance , Lapp lactase deficiency , malabsorption glucose galactose HIV positive Patient impossible follow Severe renal failure ( creatinin clearance &lt; 30 ml/min ) Concomitant treatment ketoconazole , l'itraconazole , le voriconazole posaconazole , HIV protease inhibitor , potent CYP3A4 Pgp inhibitor Simultaneous treatment rifampicin CYP3A4 inductor Hypersensitivity Xarelto one excipients Progressive bleeding , clinically relevant include lesion disease significant risk major bleeding . Concomitant treatment anticoagulant ( unfractionated heparin ( UFH ) , low molecular weight heparin ( enoxaparin , dalteparin , etc . ) , heparin derivative ( fondaparinux , etc . ) , oral anticoagulant ( warfarin , dabigatran etexilate , apixaban , etc . ) , unless relay Xarelto® `` viceversa '' , administer dos f UFH necessary maintain permeability central venous arterial catheter . Concomitant treatment acute coronary syndrome clopidogrel / Plavix® Liver transplantation Transjugular intrahepatic portosystemic shunt</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>thrombosis</keyword>
</DOC>